ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Model-Guided Rational Construction of Escherichia coli Synthetic Consortia for Enhanced 2-Methylbutyric Acid Production.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Systematically Engineering for Efficient Production of 3-Methyl-1-Butanol in Escherichia coli.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Co-utilization of glucose and xylose in synthetic Escherichia coli consortia for efficient 2-hydroxy-3-methylvalerate biosynthesis.Biotechnology for biofuels and bioproducts · 2025Article
- Model-Guided Rational Construction of Escherichia coli Synthetic Consortia for Enhanced 2-Methylbutyric Acid Production.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Synthetic consortia represent an innovative and effective platform that can significantly alleviate the metabolic burden on host organisms and enable flexible regulation of biosynthetic pathways. However, designing a stable synthetic consortium remains a significant challenge. In this study, a novel citramalate -derived pathway is first developed for 2-methylbutyric acid (2MBA) biosynthesis in an E. coli mono-culture system, achieving a titer of 678.78 ± 49.04 mg L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.